期刊文献+

对奈韦拉平耐药的HIV-1毒株诱导研究 被引量:1

Cultivation of NVP-resistant HIV-1 Stain
原文传递
导出
摘要 目的探讨对NVP耐药的I型艾滋病病毒(HIV-1)毒株的诱导方法,获得能够产生连续稳定传代的对NVP高度耐药的HIV-1毒株。方法MT4细胞中先后加入终浓度为100TCID50的HIV-1实验室毒株89.6与终浓度为10倍Ic,。的NVP药物溶液,在药物浓度不变的条件下传代,培育HIV-1病毒。提取每代培养液上清病毒RNA,逆转录后使用巢式PCR扩增HIV-1pol区基因,收集目标片段并进行测序分析。结果诱导培养所得耐药株由第5代开始与野生株相比,出现NVPIC。变化,倍数约为3倍,培养11代后,变化倍数高达178倍。此外,发生Y181C和Y188Y位点突变。结论本实验中在体外经诱导所得耐药株对NVP具有较高的耐药性,并可获得稳定传代。 Objective To investigate the method and process of the introduction of NVP-resistant HIV-1 strain, meanwhile, obtain the stable strain in vitro. Methods MT4 cells were added into the final concentration of 100 times the median tissue culture infective dose (TCIDs0) of the HIV-1 laboratory strain 89.6, and half tissue culture infective dose at concentration of 10 times the median inhibitory concentration ( ICso ) of the NVP drug solution, at the same concentration under the condition of subculture, cultivation of HIV-1 virus. Extract the virus RNA of the cutture supernatant from each generation, after reverse transcrip- tion used nested PCR to amplification of HIV-1 gene pol region, collecting the target fragment and sequencing analysis. Results The induction of the cultivation of resistant strains from the fifth generation, compared with wild strains, NVP-ICs0 began to raise about 3 times, after 11 generation of culture, change ratio as high as 178 times. In addition, Y181C and Y188Y mutation occured. Conclusions In this study, we obtain the strains highly resistant to NVP, and it can go down to the future generation stably.
出处 《国际病毒学杂志》 2016年第2期85-88,共4页 International Journal of Virology
基金 国家自然科学基金(31360033,81460511,81360259) 广西科学研究与技术开发计划课题(桂科攻14124003-1)
关键词 HIV-1 耐药 诱导方法 HIV-1 Drug resistance Inducing method
  • 相关文献

参考文献7

  • 1Walensky RP, A David P, Elena L, et al. The survival benefits of AIDS treatment in the United States. [ J]. J Infect Dis, 2006, 194 (1): 11-19.
  • 2Soo-Yon R, Tnmmy L, aideep R, et aL bistrilaution of human immunodeficieney virus type 1 protease anti reverse transcriptase mutation patterns in 4,183 persons undergoing genotypic resistance lesting. [J]. Antimierob Agents Chemother, 2004, 48(8) : 3122- 3126.
  • 3Johan V, l,otke T, Hilde A, et al. Resistance profile of etra- virine : combined analysis of baseline genotypic anti phenotypic da- ta from the randomized, controlled Phase II1 clinical studies. [ J]. Aids, 2010, 24(4) : 503-514.
  • 4Zhijun Z, Wen X, Yung-Hyo K, et al. A Novel Nonnucleoside Analogue That Inhibits Human Immunodeficiency Virus Type 1 I- solates Resistant to Current Nonnucleoside Reverse Transcriptase lnhibitors[J ]Antimierob Agents Chemother, 2007, 51 (2) : 429 437.
  • 5刘海霞,李韩平,李珏,刘永健,鲍作义,刘思扬,庄道民,吴昊,李敬云.北京市部分艾滋病患者的耐药性分析及对抗病毒治疗效果的影响[J].中华微生物学和免疫学杂志,2007,27(11):1011-1015. 被引量:9
  • 6Hanna G, Johnson VD, Richman D, et al. Patterns of resistance mutations selected by treatment of homan immunodeficiency virus tTpe I infection with zidovudine, didanosine, and nevirapine. [J]. J Infect Dis, 2000, 181(3): 904-911.
  • 7Whitcomb JM, Parkin NT, Chappey C, et al. Broad Nucleoside Reverse-Transeriptase Inhibitor Cross-Resistanee in Human lmmu- nodeficiency Virus Type 1 Clinical Isolates [J]. J Infect Dis, 2003, 188(7) : 992-1000.

二级参考文献9

  • 1Hanna GJ, Balaguera HU, Freedberg KA, et al. Drug-selected resistance mutations and non-B subtypes in antiretroviral-naive adults with established human immunodeficiency virus infection. J Infect Dis, 2003, 188(7): 986-991.
  • 2Ibe S, Hotta N, Takeo U, et al. Prevalence of drug-resistant human immunodeficiency virus type 1 in therapy-naive patients and usefulness of genotype testing. Microbiol Immunol, 2003, 47(7) : 499-505.
  • 3Johnson VA, Brun-Vezinet F, Clotet B, et al. Drug resistance mutations in HIV-1. Top HIV Med, 2003, 11(6): 215-221.
  • 4Yeni PC,, Hammer SM, Hirsch MS, et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA, 2004, 292(2): 251-265.
  • 5Sirivichayakul S, Ruxrtmgtham K, Ungsedhapand C, et al. Nucleoside analogue mutations and Q151M in HIV-1 subtype A/E infection treated with nucleoside reverse transcriptase inhibitors. AIDS, 2003, 17(13) : 1889-1896.
  • 6Bangsberg DR, Moss AR, Deeks SG. Paradoxes of adherence and drug resistance to HIV antiretroviral therapy. J Antimicrob Chemother, 2004, 53(5): 696-699.
  • 7Boden D, Hurley A, Zhang L, et al. HIV-1 drug resistance in newly infected individuals. JAMA, 1999, 282(12): 1135-1141.
  • 8Hecht FM, Colfax G, Swanson M, et al. Adherence and effectiveness of protease inhibitors in clinical practice. Presented at: Fifth Conference on Retroviruses and Opportunistic Infections; 1998; Chicago. 1998 Febl-5;5th; 107 (abstract no. 151).
  • 9Leigh Brown A J, Frost SD, Mathews WC, et al. Transmission fitness of drug-resistant human immunodeficiency virus and the prevalence of resistance in the antiretroviral-treated population. J Infect Dis, 2003, 187(4) : 683-686.

共引文献8

同被引文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部